Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status

HAYWARD, Calif.--(BUSINESS WIRE) September 25, 2017 -- Aradigm Corporation (NASDAQ: ARDM) (the " Company " ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news